查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714892

抗生素市場：2025-2030 年全球預測（按藥物類別、給藥途徑、活性頻譜、作用機制、適應症、銷售基地和分銷管道）

Antibacterial Drugs Market by Drug Class, Route of Administration, Spectrum of Activity, Mechanism of Action, Indication, Point of Sale, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗菌藥物市場預估2024年價值517.7億美元，2025年達到540.5億美元，複合年成長率為4.54%，到2030年達到675.9億美元。

介紹

主要市場統計數據
基準年2024年 517.7億美元
預計2025年 540.5億美元
預測年份 2030 675.9億美元
複合年成長率（%） 4.54%

抗生素長期以來一直是現代醫學的基石，為抵抗微生物感染提供了重要的防禦手段。在科學進步日新月異、疾病狀況不斷演變的時代，抗菌藥物的開發和利用比以往任何時候都更重要。抗生素抗藥性的持續挑戰，加上藥物研發的突破，使全世界的注意力重新集中在擴大抗菌藥物市場。本報告全面概況了抗生素領域，詳細介紹了技術創新、監管更新和新的市場機會。讀者將深入了解抗菌療法的複雜性、藥物開發、市場開發和跨地區產業動態之間的相互作用。

改變抗生素市場

抗生素市場正在經歷變革性的變化，並重塑其動態。一個關鍵的變化是研發活動的加速，推動了新化學實體的生產和現有分子配方的創新。高通量篩檢、計算建模和基因組方法等先進技術為發現對抗抗藥性菌株的新目標和新機制鋪平了道路。各地區監管機構正迅速適應不斷變化的情況，提供快速的審查流程和簡化的核准途徑，進一步刺激技術創新。

同時，醫療保健生態系統也越來越重視精準醫療和個人化治療方法。目前最需要的是針對性的抗菌藥物，以盡量減少對宿主微生物群的附帶損害。這一趨勢得到了對機制研究的積極投資的支持，以便更好地了解抗生素的作用機制。此外，聯合治療治療和輔助性治療的出現進一步完善了傳統治療模式，確保即使出現新的抗藥性機制，治療仍然可行。市場競爭的這些變化正在重新定義打入市場策略，並在全球公司之間創造新的競爭，同時也為針對特定患者群體和感染疾病特徵的利基治療方法打開了大門。

關鍵細分洞察

市場區隔的詳細分析為多方面的抗菌格局提供了關鍵見解。藥物類別根據其生化特性和作用機制對治療方法進行分類。此細分為Aminoglycosides、BETA-內醯胺類、醣肽、磺胺類藥物、大環內酯類、奎諾酮、磺胺類和四環黴素等主要類別，每種類別都透過其獨特的化合物進行進一步探索。在Aminoglycosides中，檢查了Amikacin、慶大霉素、新黴素、普拉佐米星、鏈黴素和妥布黴素等化合物，而在BETA-內醯胺類中，檢查了卡巴培南類、頭孢菌素類、單環胺基類和青黴素類化合物的特定資料。將根據達巴萬星、奧利萬星、Teicoplanin和萬古黴素等治療藥物對糖肽進行仔細檢查，並將對林可醯胺類藥物（包括克林黴素和林可黴素等藥物）、大環內酯類藥物（包括阿奇黴素、克拉黴素、紅黴素和非達黴素等產品）和奎諾酮藥物（包括Ciprofloxacin、德拉星等產品和吉米沙星。此外，也透過考慮四環黴素提供了進一步的層次，涵蓋磺胺類藥物、磺胺多辛和磺胺甲噁唑-甲氧芐啶等化合物，以及細胞週期蛋白，重點關注強力黴素、米諾四環素、四環黴素和替加環素。

另一個重要的細分是考慮給藥途徑。市場洞察力來自於研究藥物如何透過吸入、肌肉注射、靜脈注射、口服、皮下和局部方式進入人體。每種途徑都有其自身的挑戰和機會，特別是在調整劑型與患者依從性和藥物動力學特徵時。類似地，基於活性頻譜的細分將產品分為頻譜和窄頻譜藥物，這種分析區別支持臨床決策和監管核准。在基於作用機制的細分中，藥物依其抑制細胞壁合成、抑制核酸合成、抑制蛋白質合成、抑制ATP合成酶活性、抑制膜功能、抑制代謝途徑等能力進行分類。抗生素的適應症範圍廣泛，包括呼吸道感染疾病、性行為感染傳染病、皮膚感染疾病和尿道感染，也是細分的核心。同樣具有影響力的是基於銷售點的細分，它將產品分為非處方藥和處方藥，並影響分銷和市場滲透。最後，基於銷售管道的細分區分了線下和線上銷售，其中線下管道進一步透過醫院藥房和零售藥房環境中的表現進行評估。綜合起來，這些細分提供了強力的見解，使相關人員能夠調整其策略並有效回應不斷變化的市場需求。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 感染疾病的流行和傳播推動了對抗菌解決方案的需求
      • 醫院內感染發生率的增加導致對高階抗生素的需求
      • 政府加大對抗生素研發的投入
    • 限制因素
      • 抗生素相關產品召回問題
    • 機會
      • 藥物配方和輸送技術的進步為抗生素開闢了新途徑
      • 繼續公私合營，推廣抗生素
    • 任務
      • 對多重抗藥性病原體的療效有限，且有副作用的風險
  • 市場區隔分析
    • 藥物類別：由於BETA-內醯胺類藥物具有廣泛的功效和經過驗證的安全性，因此對其的需求正在成長。
    • 給藥途徑：由於給藥方便，口服給藥越來越廣泛採用。
    • 活動範圍：優先使用窄譜抗生素，以達到更精準的治療
    • 作用機轉：需要抗生素抑制核酸合成來阻止細菌生長
    • 適應症：透過創新抗菌療法改善尿道感染的管理
    • 銷售點：隨著需求的成長，改善非處方抗生素的取得途徑
    • 分銷管道：由於安全的宅配服務，線上分銷越來越受到青睞
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 抗生素市場（依藥物類別）

  • Aminoglycosides
    • Amikacin
    • 慶大霉素
    • 新黴素
    • 普拉佐米星
    • 鏈黴素
    • 妥布黴素
  • BETA-內醯胺類
    • 卡巴培南類
    • 頭孢菌素類
    • 單環胺基類
    • 青黴素
  • 糖肽
    • 達爾巴萬·辛格
    • 奧利萬星
    • Teicoplanin
    • 萬古黴素
  • 林可醯胺類
    • 克林黴素
    • 林可黴素
  • 大環內酯類
    • 阿奇黴素
    • 克拉黴素
    • 紅黴素
    • 非達黴素
  • 奎諾酮
    • Ciprofloxacin
    • 德拉沙星
    • 吉米沙星
  • 磺胺類藥物
    • 磺胺嘧啶
    • 磺胺多辛
    • 磺胺甲噁唑-甲氧芐啶
  • 四環黴素
    • 強力黴素
    • 米諾四環素
    • 四環黴素
    • 細胞週期蛋白

第7章抗生素市場（依給藥途徑）

  • 吸入
  • 肌肉注射
  • 靜脈
  • 口服
  • 皮下
  • 話題

8. 抗生素市場（依活性頻譜）

  • 頻譜
  • 窄頻頻譜

第9章抗生素市場（依作用機制）

  • 抑制細胞壁合成
  • 抑制核酸合成
  • 抑制蛋白質合成
  • ATP合成酶抑制劑
  • 膜功能抑制劑
  • 代謝途徑抑制劑

第 10 章抗生素市場（按適應症）

  • 呼吸道感染疾病
  • 性行為感染傳染病
  • 皮膚感染疾病
  • 尿道感染

第 11 章：抗生素市場銷售點

  • 非處方藥
  • 處方藥

第 12 章抗生素市場（依通路）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 線上

13. 美洲抗生素市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太抗生素市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲抗生素市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Allecra Therapeutics GmbH
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Century Pharmaceuticals Ltd.
  • Cipla Limited
  • Debiopharm Group
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Entasis Therapeutics by Innoviva, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Services, Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Saphnix Life Sciences
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8012

The Antibacterial Drugs Market was valued at USD 51.77 billion in 2024 and is projected to grow to USD 54.05 billion in 2025, with a CAGR of 4.54%, reaching USD 67.59 billion by 2030.

Introduction

KEY MARKET STATISTICS
Base Year [2024] USD 51.77 billion
Estimated Year [2025] USD 54.05 billion
Forecast Year [2030] USD 67.59 billion
CAGR (%) 4.54%

Antibacterial drugs have long been a cornerstone of modern medicine, offering critical defense against microbial infections. In an era marked by rapid scientific advances and an evolving disease profile, the development and utilization of antibacterial agents remain as crucial as ever. The ongoing challenge of antimicrobial resistance, coupled with breakthroughs in pharmaceutical research and development, has catalyzed a renewed global focus on expanding the antibacterial drugs market. This report provides a comprehensive overview of the current state of antibacterial drugs, detailing technological innovations, regulatory updates, and emerging market opportunities. Readers will gain insight into the complexity of antibacterial therapies and the interplay between drug development, market segmentation, and regional industry dynamics.

Transformative Shifts in the Landscape

The antibacterial drugs market has witnessed transformative changes that are reshaping its dynamics. Key shifts include an acceleration in research and development activities that are driving innovations across the production of both novel compounds and restructured formulations of existing molecules. Advanced technologies such as high-throughput screening, computational modeling, and genomic approaches have paved the way for the discovery of new targets and mechanisms to combat resistant strains. Regulatory agencies across different regions are adapting faster to the evolving scenario by offering expedited review processes and streamlined pathways to approval, further spurring innovation.

In parallel, the healthcare ecosystem is increasingly prioritizing precision medicine and individualized therapeutic regimens. The need for targeted antibacterial agents that minimize collateral damage to the host microbiome is at the forefront. This trend is supported by robust investments in mechanistic studies that provide greater insight into the modes of action of antibacterial drugs. In addition, the emergence of combination therapies and adjuvant treatments has added a layer of sophistication to traditional treatment paradigms, ensuring that therapies remain viable even in the face of emerging resistance mechanisms. Collectively, these transformative shifts have redefined market entry strategies and built new layers of competition among global players, while simultaneously opening the door for niche interventions that cater to specific patient demographics and infection profiles.

Key Segmentation Insights

An in-depth analysis of market segmentation provides critical insight into the multifaceted antibacterial drugs landscape. The drug class segmentation categorizes treatments by the biochemical properties and mechanisms of action. This segmentation is broken down into major classes such as Aminoglycosides, Beta-Lactams, Glycopeptides, Lincosamides, Macrolides, Quinolones, Sulfonamides, and Tetracyclines; each of which is further studied by its unique compounds. Within the Aminoglycosides category, compounds including Amikacin, Gentamicin, Neomycin, Plazomicin, Streptomycin, and Tobramycin are examined, while the Beta-Lactams category delves into Compound-specific data for Carbapenems, Cephalosporins, Monobactams, and Penicillins. Glycopeptides are scrutinized based on therapies such as Dalbavancin, Oritavancin, Teicoplanin, and Vancomycin, and similar detailed analytical approaches are applied to Lincosamides with agents like Clindamycin and Lincomycin, Macrolides with products including Azithromycin, Clarithromycin, Erythromycin, and Fidaxomicin, followed by Quinolones examining Ciprofloxacin, Delafloxacin, and Gemifloxacin. Additional layers are provided by examining Sulfonamides, which cover compounds such as Sulfadiazine, Sulfadoxine, and Sulfamethoxazole-Trimethoprim, together with Tetracyclines that focus on Doxycycline, Minocycline, Tetracycline, and Tigecycline.

Another important segmentation considers routes of administration. Market insights are deduced from examining how drugs are delivered into the system via Inhalation, Intramuscular, Intravenous, Oral, Subcutaneous, and Topical means. Each route presents unique challenges and opportunities, particularly when aligning dosage forms with patient compliance and pharmacokinetic profiles. Similarly, segmentation based on the spectrum of activity categorizes products as Broad-Spectrum versus Narrow-Spectrum agents, an analytical distinction that supports both clinical decision-making and regulatory approvals. Further refinement is seen in segmentation according to mechanism of action, where drugs are grouped based on their ability to inhibit cell wall synthesis, nucleic acid synthesis, protein synthesis, ATP synthase activity, or affect membrane functions and metabolic pathways. The wide-ranging indications for antibacterial drugs are also central to segmentation, with clinical applications spanning Respiratory Infections, Sexually Transmitted Infections, Skin Infections, and Urinary Tract Infections. Equally influential is the segmentation based on the point of sale, delineating products as Over-The-Counter or Prescription Drugs, which affects distribution and market penetration. Finally, a segmentation based on the distribution channel distinguishes between Offline and Online sales, with Offline channels being further evaluated by their performance in Hospital Pharmacy and Retail Pharmacy environments. These segmentation dimensions collectively provide robust insights that enable stakeholders to tailor their strategies and respond effectively to the evolving market demands.

Based on Drug Class, market is studied across Aminoglycosides, Beta-Lactams, Glycopeptide, Lincosamides, Macrolides, Quinolones, Sulfonamides, and Tetracyclines. The Aminoglycosides is further studied across Amikacin, Gentamicin, Neomycin, Plazomicin, Streptomycin, and Tobramycin. The Beta-Lactams is further studied across Carbapenems, Cephalosporins, Monobactams, and Penicillins. The Glycopeptide is further studied across Dalbavancin, Oritavancin, Teicoplanin, and Vancomycin. The Lincosamides is further studied across Clindamycin and Lincomycin. The Macrolides is further studied across Azithromycin, Clarithromycin, Erythromycin, and Fidaxomicin. The Quinolones is further studied across Ciprofloxacin, Delafloxacin, and Gemifloxacin. The Sulfonamides is further studied across Sulfadiazine, Sulfadoxine, and Sulfamethoxazole-Trimethoprim. The Tetracyclines is further studied across Doxycycline, Minocycline, Tetracycline, and Tigecycline.

Based on Route of Administration, market is studied across Inhalation, Intramuscular, Intravenous, Oral, Subcutaneous, and Topical.

Based on Spectrum of Activity, market is studied across Broad-Spectrum and Narrow-Spectrum.

Based on Mechanism of Action, market is studied across Inhibit Cell Wall Synthesis, Inhibit Nucleic Acid Synthesis, Inhibit Protein Synthesis, Inhibitor of ATP Synthase, Inhibitors of Membrane Function, and Inhibitors of Metabolic Pathways.

Based on Indication, market is studied across Respiratory Infections, Sexually Transmitted Infections, Skin Infections, and Urinary Tract Infections.

Based on Point of Sale, market is studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.

Key Regional Insights

The antibacterial drugs market exhibits significant heterogeneity across different global regions, reinforcing the need for tailored strategies that accommodate local dynamics. In the Americas, advanced healthcare infrastructure and heightened public awareness about antimicrobial resistance have driven significant investment in research, fostering a dynamic market characterized by rapid adoption of innovative therapies. Meanwhile, Europe, Middle East & Africa has witnessed a consolidation of regulatory policies and a strategic focus on combating resistance through coordinated public health initiatives and cross-border collaborations. Regulatory frameworks in these regions promote accelerated approvals for breakthrough technologies while ensuring that safety and efficacy remain paramount. Across Asia-Pacific, rapid economic growth, coupled with increasing healthcare expenditures and expanding access to advanced medical practices, has intensified the demand for both new and improved antibacterial agents. In these regions, the burgeoning middle class and improved health literacy have collectively encouraged wider use of both prescription and over-the-counter treatments. These regional insights underscore the importance of considering cultural, economic, and regulatory differences when devising market entry and expansion strategies in the antibacterial drugs domain.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

The antibacterial drugs market is marked by the active involvement of several key companies, each contributing to the industry's forward momentum through a blend of innovation, strategic mergers, and robust product portfolios. Major players such as Abbott Laboratories, AbbVie Inc., and Allecra Therapeutics GmbH continue to invest heavily in cutting-edge research while expanding their product offerings. Astellas Pharma Inc. and AstraZeneca PLC, with their rich histories and extensive networks, consistently drive market penetration through innovative therapeutic strategies. Bausch Health Companies Inc. and Bayer AG have strengthened their positions by harnessing diagnostic advancements that enhance treatment specificity, while Bristol-Myers Squibb Company and Century Pharmaceuticals Ltd. maintain their commitment to broadening therapeutic horizons. Companies like Cipla Limited and Debiopharm Group couple extensive market reach with robust research endeavors. Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, and Entasis Therapeutics by Innoviva, Inc. have also cut a niche for themselves by concentrating on targeted antibacterial solutions, ensuring that diverse patient needs are met. F. Hoffmann-La Roche AG and GlaxoSmithKline PLC continue to be stalwarts of the industry, offering a wide range of products supported by significant research investments. Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, and Iterum Therapeutics PLC have further diversified the competitive landscape by merging traditional practices with modern science. Johnson & Johnson Services, Inc. along with Kyorin Pharmaceutical Co., Ltd., Lupin Limited, and Melinta Therapeutics LLC also play pivotal roles, influencing global trends and ensuring product accessibility. The contributions of Merck & Co., Inc., Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd., Novartis AG, and Pfizer Inc. are pivotal in setting benchmarks for excellence, with Sanofi S.A. and Saphnix Life Sciences strengthening the research interface between academia and the pharmaceutical industry. Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd. round off the cohort of influential companies that continuously shape market trends and propel innovative antibacterial therapeutics.

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Allecra Therapeutics GmbH, Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Century Pharmaceuticals Ltd., Cipla Limited, Debiopharm Group, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Iterum Therapeutics PLC, Johnson & Johnson Services, Inc., Kyorin Pharmaceutical Co., Ltd., Lupin Limited, Melinta Therapeutics LLC, Merck & Co., Inc., Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Saphnix Life Sciences, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders in the antibacterial drugs market are encouraged to adopt a multi-pronged strategic approach in response to the continuously evolving landscape. First, stakeholders must significantly increase investments in basic and translational research targeting emerging resistance patterns, harnessing modern technologies that accelerate compound discovery and the development of efficacy-enhancing formulations. A close alliance with academic institutions and biotechnology innovators will be crucial to translating research insights into viable products. Second, companies should streamline their regulatory interphase processes and foster advocacy channels with government bodies to secure accelerated approvals without compromising on safety or efficacy benchmarks. This collaborative approach will be particularly vital in regions where regulatory frameworks are undergoing rapid transitions.

In addition, an optimized segmentation strategy can serve as a competitive differentiator. Organizations should invest in sophisticated market analytics to track evolving patient and prescriber needs, thereby allowing them to refine product portfolios based on drug class, route of administration, and spectrum of activity. Tailoring therapeutic solutions across diverse indications such as respiratory, urinary, skin, and sexually transmitted infections will enhance market relevance. Moreover, one should also focus on mechanisms of action as an integral segmentation tool, categorizing treatments according to their precision in inhibiting pathogen structures, metabolic pathways, or other critical processes. This granularity not only informs targeted marketing campaigns but also assists in achieving regulatory endorsements.

A forward-thinking distribution strategy is equally critical. Industry leaders should leverage both offline and online channels to broaden market reach while ensuring that product quality and patient safety remain uncompromised. Strategic alliances with hospital pharmacies and retail networks can drive penetration in traditionally robust offline sectors, while collaborative digital initiatives can capture the growing segment of online buyers. Finally, a clear focus on sustainability, patient-centric outcomes, and ethical drug promotion practices will build trust with healthcare professionals and end-consumers alike. Embracing these recommendations will empower industry leaders to not only navigate the complex antibacterial landscape but also to seize opportunities for sustainable growth and competitive advantage.

Conclusion

In conclusion, the antibacterial drugs market is at a pivotal juncture, driven by a synthesis of scientific innovation, regulatory reform, and robust market segmentation. The evolving landscape has redefined research paradigms and spurred the growth of innovative therapies that effectively challenge drug-resistant pathogens. A comprehensive understanding of segmentation-across drug classes, administration routes, spectrum of activity, mechanisms of action, clinical indications, points of sale, and distribution channels-proves vital to navigating this multifaceted market. The regional disparities and specific market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific further underscore the importance of localized and adaptive strategies.

The collective efforts of leading companies have paved the way for advancements that not only fulfill current market needs but also anticipate future trends. With a focus on strategic investments, partnerships, and technological integration, the antibacterial drugs landscape is poised for robust growth, enabling providers to deliver more precise and effective treatments. Ultimately, the synthesis of detailed market insights and actionable recommendations equips stakeholders with the necessary framework to navigate the ongoing challenges and tap into emerging growth opportunities in a competitive environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence and spread of infectious diseases enhancing the need for antibacterial solutions
      • 5.1.1.2. Increasing incidence of hospital-acquired infections need for advanced antibacterial drugs
      • 5.1.1.3. Rising government initiatives for antibacterial drug research and development
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall issue associated with antibacterial drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug formulation and delivery technology opening new avenues for antibacterial drugs
      • 5.1.3.2. Ongoing public-private collaboration for advancement of antibacterial drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited efficacy against multi-drug resistant pathogens and risk of adverse side effects
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing need of Beta-Lactams due to their broad-spectrum efficacy, and proven safety profile
    • 5.2.2. Route of Administration: Rising adoption of oral antibacterial drugs due to their ease of administration
    • 5.2.3. Spectrum of Activity: Prefernce for narrow-spectrum antibacterial drugs for more precise treatment
    • 5.2.4. Mechanism of Action: Need for an antibacterial drug that inhibits nucleic acid synthesis to prevent bacteria from proliferating
    • 5.2.5. Indication: Advancing precision in urinary tract infection management through innovative antibacterial therapies
    • 5.2.6. Point of Sale: Growing demand for over-the-counter antibacterial drug to enhancing accessibility
    • 5.2.7. Distribution Channel: Rising preference for online to secure home delivery services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibacterial Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Aminoglycosides
    • 6.2.1. Amikacin
    • 6.2.2. Gentamicin
    • 6.2.3. Neomycin
    • 6.2.4. Plazomicin
    • 6.2.5. Streptomycin
    • 6.2.6. Tobramycin
  • 6.3. Beta-Lactams
    • 6.3.1. Carbapenems
    • 6.3.2. Cephalosporins
    • 6.3.3. Monobactams
    • 6.3.4. Penicillins
  • 6.4. Glycopeptide
    • 6.4.1. Dalbavancin
    • 6.4.2. Oritavancin
    • 6.4.3. Teicoplanin
    • 6.4.4. Vancomycin
  • 6.5. Lincosamides
    • 6.5.1. Clindamycin
    • 6.5.2. Lincomycin
  • 6.6. Macrolides
    • 6.6.1. Azithromycin
    • 6.6.2. Clarithromycin
    • 6.6.3. Erythromycin
    • 6.6.4. Fidaxomicin
  • 6.7. Quinolones
    • 6.7.1. Ciprofloxacin
    • 6.7.2. Delafloxacin
    • 6.7.3. Gemifloxacin
  • 6.8. Sulfonamides
    • 6.8.1. Sulfadiazine
    • 6.8.2. Sulfadoxine
    • 6.8.3. Sulfamethoxazole-Trimethoprim
  • 6.9. Tetracyclines
    • 6.9.1. Doxycycline
    • 6.9.2. Minocycline
    • 6.9.3. Tetracycline
    • 6.9.4. Tigecycline

7. Antibacterial Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intramuscular
  • 7.4. Intravenous
  • 7.5. Oral
  • 7.6. Subcutaneous
  • 7.7. Topical

8. Antibacterial Drugs Market, by Spectrum of Activity

  • 8.1. Introduction
  • 8.2. Broad-Spectrum
  • 8.3. Narrow-Spectrum

9. Antibacterial Drugs Market, by Mechanism of Action

  • 9.1. Introduction
  • 9.2. Inhibit Cell Wall Synthesis
  • 9.3. Inhibit Nucleic Acid Synthesis
  • 9.4. Inhibit Protein Synthesis
  • 9.5. Inhibitor of ATP Synthase
  • 9.6. Inhibitors of Membrane Function
  • 9.7. Inhibitors of Metabolic Pathways

10. Antibacterial Drugs Market, by Indication

  • 10.1. Introduction
  • 10.2. Respiratory Infections
  • 10.3. Sexually Transmitted Infections
  • 10.4. Skin Infections
  • 10.5. Urinary Tract Infections

11. Antibacterial Drugs Market, by Point of Sale

  • 11.1. Introduction
  • 11.2. Over-The-Counter Drugs
  • 11.3. Prescription Drugs

12. Antibacterial Drugs Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
    • 12.2.1. Hospital Pharmacy
    • 12.2.2. Retail Pharmacy
  • 12.3. Online

13. Americas Antibacterial Drugs Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Antibacterial Drugs Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Antibacterial Drugs Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Oxford Drug Design secures GBP 1M funding to advance uUTI therapeutics
    • 16.3.2. FDA approval of Emblaveo for resistant gram-negative infections
    • 16.3.3. CARB-X invests in innovative peptide antibiotic targeting gram-negative bacteria
    • 16.3.4. Wockhardt secures CDSCO approval for Miqnaf for innovative CABP treatment
    • 16.3.5. Zai Lab and Pfizer forge strategic collaboration on novel antibacterial drug XACDURO
    • 16.3.6. FDA approves ORLYNVAH for uncomplicated urinary tract infections
    • 16.3.7. Orchid Pharma partner with Cipla Unite to launch new antibiotic in India
    • 16.3.8. Allecra Therapeutics and Acino secure exclusive licensing deal to commercialize EXBLIFEP antibiotic
    • 16.3.9. Lupin Launches generic Doxycycline injection in US
    • 16.3.10. FDA approves Zevtera for multiple bacterial infections
    • 16.3.11. Lupin secures FDA approval for generic doxycycline injection
    • 16.3.12. Basilea acquires novel preclinical antibiotics program from Spexis
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. Pfizer Inc.
    • 16.4.2. Lupin Limited
    • 16.4.3. Cipla Limited
    • 16.4.4. Glenmark Pharmaceuticals Limited

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Allecra Therapeutics GmbH
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bausch Health Companies Inc.
  • 7. Bayer AG
  • 8. Bristol-Myers Squibb Company
  • 9. Century Pharmaceuticals Ltd.
  • 10. Cipla Limited
  • 11. Debiopharm Group
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. Entasis Therapeutics by Innoviva, Inc.
  • 15. F. Hoffmann-La Roche AG
  • 16. GlaxoSmithKline PLC
  • 17. Glenmark Pharmaceuticals Limited
  • 18. Hikma Pharmaceuticals PLC
  • 19. Iterum Therapeutics PLC
  • 20. Johnson & Johnson Services, Inc.
  • 21. Kyorin Pharmaceutical Co., Ltd.
  • 22. Lupin Limited
  • 23. Melinta Therapeutics LLC
  • 24. Merck & Co., Inc.
  • 25. Nabriva Therapeutics PLC by Sumitomo Pharma Co., Ltd.
  • 26. Novartis AG
  • 27. Pfizer Inc.
  • 28. Sanofi S.A.
  • 29. Saphnix Life Sciences
  • 30. Shionogi & Co., Ltd.
  • 31. Sun Pharmaceutical Industries Limited
  • 32. Taj Pharmaceuticals Limited
  • 33. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBACTERIAL DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. ANTIBACTERIAL DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. ANTIBACTERIAL DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PLAZOMICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOBRAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MONOBACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DALBAVANCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORITAVANCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY FIDAXOMICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DELAFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY GEMIFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFADOXINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFAMETHOXAZOLE-TRIMETHOPRIM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MINOCYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY BROAD-SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY NARROW-SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBIT CELL WALL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBIT NUCLEIC ACID SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBIT PROTEIN SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBITOR OF ATP SYNTHASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBITORS OF MEMBRANE FUNCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INHIBITORS OF METABOLIC PATHWAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 91. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 92. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 93. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 94. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 99. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 101. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 108. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 109. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 110. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 111. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 113. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 116. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 121. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 125. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 126. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 127. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 129. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 132. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 134. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 136. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 139. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 140. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 141. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 142. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 143. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 145. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 146. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 148. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 150. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 152. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 153. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 154. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 157. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 158. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 159. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 161. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 164. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 166. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 168. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 169. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 170. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 171. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 172. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 200. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 202. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 204. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 206. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 208. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 212. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 214. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 216. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 218. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 219. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 220. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 221. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 222. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 223. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 224. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 225. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 227. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 228. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 230. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 232. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 234. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 235. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 236. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 237. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 238. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 239. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 240. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 241. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 243. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 244. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 245. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 246. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 248. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 249. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 250. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 251. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 252. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 253. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 254. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 255. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 256. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 257. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 259. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 260. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 262. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 264. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 265. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 266. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 267. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 268. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 269. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 270. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 271. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 272. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 273. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 275. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 276. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 277. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 278. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 280. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 281. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 282. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 283. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 284. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 285. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 286. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 287. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 288. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 289. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 290. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 291. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 292. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 293. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 294. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 296. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 297. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 298. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 299. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 300. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 301. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 302. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 304. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 305. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 307. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 308. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 309. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 310. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 312. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 313. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 314. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 315. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 316. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 317. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 318. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 319. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 320. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 321. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 322. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 323. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 324. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 325. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY POINT OF SALE, 2018-2030 (USD MILLION)
  • TABLE 326. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY BETA-LACTAMS, 2018-2030 (USD MILLION)
  • TABLE 331. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY GLYCOPEPTIDE, 2018-2030 (USD MILLION)
  • TABLE 332. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY LINCOSAMIDES, 2018-2030 (USD MILLION)
  • TABLE 333. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD MILLION)
  • TABLE 334. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, 2018-2030 (USD MILLION)
  • TABLE 335. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD MILLION)
  • TABLE 336. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD MILLION)
  • TABLE 337. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 338. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
  • TABLE 339. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)

TABLE 340.